Key result
Structured management of co-occurring venous and arterial thromboembolism requires balancing patient-specific thrombotic and bleeding risks.
Why the study?
Co-occurrence of arterial and venous thromboses is common, but whether patients require anticoagulation, antiplatelet therapy, or both remains a clinical management challenge.
Does the patient with venous and arterial thrombosis require anticoagulation, antiplatelet therapy, or both?
Does the patient with venous and arterial thrombosis require anticoagulation, antiplatelet therapy, or both?
Provides a structured clinical framework for managing the complex antithrombotic needs of patients with concurrent venous and arterial thromboembolic risks.
May guide antithrombotic decisions in concurrent venous-arterial events; leaves open prospective trials for standardization.
Arterial and venous thromboses are classically considered distinct disease states, with arterial thrombosis mediated predominantly by platelets and therefore, treated with antiplatelet therapy, and venous thrombosis mediated by the plasmatic coagulation system and treated with anticoagulation. However, co-occurrence of arterial and venous events is common, and there is increasing evidence of shared risk factors and pathophysiologic overlap. This presents a management challenge: does the patient with venous and arterial thrombosis, require anticoagulation, antiplatelet therapy, or both? Herein, we present a structured approach to the evaluation and management of patients with venous thrombosis who are also at risk for or have a history of an arterial thromboembolic event. We emphasize the importance of defining the indications for antithrombotic therapy, as well as the evaluation of factors that influence both thrombotic and bleeding risk, including disorder-specific and patient-specific factors, as well as the inherent risk balance of antithrombotic therapy regimens. We illustrate this approach in 4 cases, discussing the unique considerations and recent updates in the management of venous thrombosis, acute noncardioembolic ischemic stroke, coronary artery disease and acute myocardial infarction, and peripheral artery disease after revascularization.
No takes yet. Share an insight, caveat, or question.
May et al. (2024) conducted a review in Co-occurrence of venous and arterial thromboembolism (n=4). Anticoagulation, antiplatelet therapy, or both was evaluated. A structured approach to managing the co-occurrence of venous and arterial thromboembolism requires evaluating disorder-specific and patient-specific factors to balance thrombotic and bleeding risks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: